Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic profiling of tissue and circulating tumour DNA

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.10.18
Views: 195
Rating:

Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, Utah

Dr Neeraj Agarwal speaks with ecancer at ESMO 2018 in Munich about the pan-cancer assessment of BRCA1/2 genomic alterations (GAs) by comprehensive genomic profiling (CGP) of tissue and circulating tumour DNA.

Dr Agarwal found that BRCA1/2 alterations were prevalent in multiple other cancer types.

He goes on to say that, although PARP inhibitors have an efficacy when used to treat ovarian cancer due to the BRCA1/2 alterations, we cannot assume they will be effective in other cancers due to needing a certain level of genome wide loss-of-heterozygosity.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

BGICC conference


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation